ClinicalTrials.gg
CompletedNCT03414294Updated Jan 28, 2020

A Study to Evaluate the Safety of K-755 in Healthy Volunteers

A Phase 1 interventional study of K-755 Part A (SAD) and Placebo Part A (SAD) in Healthy, sponsored by Kowa Company, Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-28.

Sponsored by Kowa Company, Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a Phase 1 study designed to explore the safety, tolerability and pharmacokinetics of K-755 following oral administration to healthy male and female volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Kowa Company, Ltd. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
  2. Males or females, of any race, between 18 and 45 years of age.
  3. (BMI) between 18.0 and 28.0 kg/m2.
  4. Hematology, clinical chemistry, and urinalysis test results within the reference ranges or showing no deviations, as judged by the Investigator.
  5. No clinically significant abnormalities on the basis of medical history, physical examination findings, and vital signs.
  6. All females must have a negative serum pregnancy test.
  7. Able and willing to comply with the protocol and study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Female subject who are pregnant or breastfeeding.
  2. Subject with presence of active or recurring cardiovascular, pulmonary, renal, endocrine, hepatic, neurologic, psychiatric, immunologic, hematologic, gastrointestinal, or metabolic disease requiring medical treatment.
  3. Subject with any surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of K-755.
  4. Subject with presence of an active or within the past 5 years a malignancy of any type, other than basal cell carcinoma of the skin.
  5. Subject has a history of type 1 to any medication and/or clinically relevant food allergies.
  6. Subject has a history of drug addiction.
  7. Subject has a positive screen for drugs of abuse, cotinine or alcohol.
  8. Subject has a history of regular alcohol consumption within 6 months of the study.
  9. Subject has smoked tobacco within 6 months prior to Check-in, or has used non-inhaled tobacco- or nicotine-containing products within 3 months prior to Check-in.
  10. Subject has used prescription or over-the-counter medications, dietary/nutritional supplements (except paracetamol or vitamin supplements)
  11. Subject has used medications (oral, inhaled, parenteral, or topical) within 30 days or 5 half-lives (whichever is longer) before study drug administration.
  12. Subject has participated in an drug study within 30 days or 5 half-lives (whichever is longer) before study drug administration.
  13. Subject has a positive screen for surface antigen, virus antibody, or types 1 and 2 antigens/antibodies.
  14. Subject has had a clinically significant acute illness within 4 weeks or other illness within 5 days before the first study drug administration.
  15. Subject or a family member of the subject is a member of the professional or ancillary personnel working at the investigative site involved in the study.
  16. Not suitable for entry into the study in the opinion of the Investigator.
  17. Receipt of blood products within 2 months prior to Check-in.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    K-755 Part A (SAD)

    Drug: K-755 Part A (SAD)

  • Placebo comparator
    Placebo Part A (SAD)

    Drug: Placebo Part A (SAD)

  • Experimental
    K-755 Part B (MAD)

    Drug: K-755 Part B (MAD)

  • Placebo comparator
    Placebo Part B (MAD)

    Drug: Placebo Part B (MAD)

  • Experimental
    K-755 Part C (FE)

    Drug: K-755 Part C (FE)

  • Experimental
    K-755 Part D (FE)

    Drug: K-755 Part D (FE)

  • Experimental
    K-755 Part E (MAD)

    Drug: K-755 Part E (MAD)

  • Placebo comparator
    Placebo Part E (MAD)

    Drug: Placebo Part E (MAD)

Interventions

  • DrugK-755 Part A (SAD)

    Single ascending dose (SAD). There will be 7 cohorts in the Part A. Three quarters of subjects will receive K-755 tablet orally in a double-blind fashion.

  • DrugPlacebo Part A (SAD)

    Single ascending dose (SAD). In Part A, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.

  • DrugK-755 Part B (MAD)

    Multiple ascending dose (MAD). There will be 4 cohorts in the Part B. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.

  • DrugPlacebo Part B (MAD)

    Multiple ascending dose (MAD). In Part B, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.

  • DrugK-755 Part C (FE)

    Food effect (FE). All subjects in Part C will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.

  • DrugK-755 Part D (FE)

    Food effect (FE). All subjects in Part D will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.

  • DrugK-755 Part E (MAD)

    Multiple ascending dose (MAD). There will be 2 cohorts in the Part E. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.

  • DrugPlacebo Part E (MAD)

    Multiple ascending dose (MAD). In the Part E. One quarter of subjects will receive placebo tablet orally in a double-blind fashion.

06

What researchers measure

Primary outcomes

  1. Part A, B, C, D and E: Incidence and severity of Adverse Events

    A treatment-emergent adverse events (TEAE) will be summarized by treatment and overall, and summarized for each treatment by severity and relationship to study drug. All TEAEs leading to withdrawal, or SAEs, will be summarized.

    Time frame: Up to 28 days after last administration

  2. Part A, B, C, D and E: Number of subjects with clinical laboratory test abnormalities

    The clinical laboratory will include hematology (hematocrit, hemoglobin, mean cell hemoglobin, mean cell hemoglobin concentration, mean cell volume, platelet count, red blood cell count, white blood cell count), clinical chemistry (alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, blood urea nitrogen, calcium, chloride, cholesterol, creatinine, creatine phosphokinase, direct bilirubin, estimated glomerular filtration rate, gamma glutamyl transferase, glucose. inorganic phosphate, iron, lactate dehydrogenase, phosphorus, potassium, sodium, total bilirubin, total CO2, total protein, triglyceride, urea, uric acid), and urinalysis (bilirubin, blood, color and appearance, glucose, ketones, leukocyte esterase, nitrite, pH, protein, specific gravity, urobilinogen, microscopic examination, electrolytes). Abnormality will be determined by the investigator.

    Time frame: Up to 28 days after last administration

  3. Part A, B, C, D and E: Number of subjects with vital signs abnormalities

    The vital sign will include blood pressure (mmHg), pulse rate (bpm), respiratory rate (breaths/min), and body temperature (degree Celsius). Abnormality will be determined by the investigator.

    Time frame: Up to 28 days after last administration

  4. Part A, B, C, D and E: Number of subjects with clinically significant change in body weight

    Change in body weight (kg) at baseline and post dose will be measured. Clinical significance will be determined by the investigator.

    Time frame: Up to 28 days after last administration

  5. Part A, B, C, D and E: Number of subjects with abnormal findings in physical examinations

    The physical examination will typically include general appearance, head and neck, eyes, ear, nose and throat, lymph nodes, thyroid, cardiovascular, respiratory, abdomen, nervous, skin, musculoskeletal, peripheral vascular and extremities and be performed at Investigator's discretion based on reported symptoms. Abnormality will be determined by the investigator.

    Time frame: Up to 28 days after last administration

Secondary outcomes

  1. Part A: AUC0-inf of K-755

    Area under the plasma concentration-time curve (AUC) from time zero extrapolated to infinity

    Time frame: Up to 28 days after single administration

  2. Part A: AUC0-tlast of K-755

    AUC from time zero to the time of the last measurable concentration

    Time frame: Up to 28 days after single administration

  3. Part A: Cmax of K-755

    Maximum plasma concentration

    Time frame: Up to 28 days after single administration

  4. Part A: Tmax of K-755

    Time of the observed maximum plasma concentration

    Time frame: Up to 28 days after single administration

  5. Part A: t1/2 of K-755

    Terminal plasma elimination half-life

    Time frame: Up to 28 days after single administration

  6. Part B: AUC0-τ of K-755

    AUC over the dosing interval

    Time frame: Up to 28 days after repeated administration

  7. Part B: Cmax of K-755

    Maximum plasma concentration

    Time frame: Up to 28 days after repeated administration

  8. Part B: Tmax of K-755

    Time of the observed maximum plasma concentration

    Time frame: Up to 28 days after repeated administration

  9. Part B: t1/2 of K-755

    Terminal plasma elimination half-life

    Time frame: Up to 28 days after repeated administration

  10. Part C: AUC0-inf of K-755

    Area under the plasma concentration-time curve (AUC) from time zero extrapolated to infinity

    Time frame: Up to 14 days after single administration

  11. Part C: AUC0-tlast of K-755

    AUC from time zero to the time of the last measurable concentration

    Time frame: Up to 14 days after single administration

  12. Part C: Cmax of K-755

    Maximum plasma concentration

    Time frame: Up to 14 days after single administration

  13. Part C: Tmax of K-755

    Time of the observed maximum plasma concentration

    Time frame: Up to 14 days after single administration

  14. Part C: t1/2 of K-755

    Terminal plasma elimination half-life

    Time frame: Up to 14 days after single administration

  15. Part D: AUC0-inf of K-755

    Area under the plasma concentration-time curve (AUC) from time zero extrapolated to infinity

    Time frame: Up to 14 days after single administration

  16. Part D: AUC0-tlast of K-755

    AUC from time zero to the time of the last measurable concentration

    Time frame: Up to 14 days after single administration

  17. Part D: Cmax of K-755

    Maximum plasma concentration

    Time frame: Up to 14 days after single administration

  18. Part D: Tmax of K-755

    Time of the observed maximum plasma concentration

    Time frame: Up to 14 days after single administration

  19. Part D: t1/2 of K-755

    Terminal plasma elimination half-life

    Time frame: Up to 14 days after single administration

  20. Part E: AUC0-τ of K-755

    AUC over the dosing interval

    Time frame: Up to 14 days after single administration

  21. Part E: Cmax of K-755

    Maximum plasma concentration

    Time frame: Up to 14 days after single administration

  22. Part E: Tmax of K-755

    Time of the observed maximum plasma concentration

    Time frame: Up to 14 days after single administration

  23. Part E: t1/2 of K-755

    Terminal plasma elimination half-life

    Time frame: Up to 14 days after single administration

07

Study locations

1 site
  • CMAX, Clinical Research Pty Ltd
    Adelaide, South Australia 5000, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Nov 2019, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2018
First posted
Jan 29, 2018
StartActual
Feb 27, 2018
Primary completionActual
Nov 14, 2019
CompletionActual
Nov 14, 2019
Last update
Jan 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03414294
Lead sponsor
Kowa Company, Ltd.
Responsible party
Sponsor
First posted
Jan 29, 2018
Start date
Feb 27, 2018
Primary completion
Nov 14, 2019
Completion
Nov 14, 2019
Last update
Jan 28, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion